Propanc Biopharma files draft information statement on restricted stock issuances
PPCB•Restricted stock issuances authorized
Propanc Biopharma shareholders authorized new restricted common stock issuances totaling 3.5 million shares for officers, directors, consultants and legal advisers.
The largest grant is 1 million restricted shares to CEO James Nathanielsz. The remaining awards are largely 250,000 shares each across multiple recipients.
The company reported 3,503,116 common shares outstanding as of July 24, 2026, before the new issuances.
